Significance of incidental intra-articular and peri-articular FDG avid foci on PET/CT

Cohen-Levy, Wayne B.; Pretell-Mazzini, Juan; Singer, Adam D.; Subhawong, Ty K.; Greif, Dylan N.; Jose, Jean

doi:10.1177/0284185118770901

Cited by 5 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some case reports state that TSGCT has a high accumulation of FDG, mimicking malignancy and metastasis [ 16 – 21 ]. The mean SUVmax in patients with TSGCT was higher than the SUVmax in those with benign and non-physiologic pathologies [ 17 ]. West et al reported that TSGCT was related to conditions manifesting features of both reactive inflammatory disorders and clonal neoplastic proliferations involved with abnormal CSF1 expression [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

“…In patients with diffuse-type TSGCT, joint hemorrhage and repeated local recurrence have been reported to cause joint destruction [ 11 ]. On 18 F-FDG-PET, TSGCT has a high accumulation of fluorodeoxyglucose (FDG) despite it being a benign tumor [ 16 , 17 ]. However, few reports have been published regarding the detailed evaluation of TSGCT using 18 F-FDG-PET/CT.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Imaging characteristics of tenosynovial giant cell tumors on 18F-fluorodeoxyglucose positron emission tomography/computed tomography: a retrospective observational study

Mizuta

Oshiro

Tsuha

et al. 2023

BMC Musculoskelet Disord

View full text Add to dashboard Cite

Background 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) is useful for assessing location, metastasis, staging, and recurrence of malignant tumors. Tenosynovial giant cell tumor (TSGCT) is a benign tumor; however, some studies have reported that TSGCTs have a high uptake of FDG. Few studies have reported on the detailed evaluation of TSGCT using 18F-FDG-PET/CT. The purpose of the current study is to evaluate the image characteristics and locations, particularly where possible, with or without, extra-articular invasion from TSGCT of the knee in 18F-FDG-PET/CT could occur. Methods We retrospectively reviewed the patients with TSGCT who were diagnosed pathologically either by biopsy or surgical specimen. Furthermore, we evaluated the difference of the maximum standardized uptake value (SUVmax) between diffused TSGCT with extra-articular invasion and TSGCT with intra-articular localization in the knee. Results The study consisted of 20 patients with TSGCT. The mean SUVmax of TSGCT was 12.0 ± 6.50. There were five patients with TSGCT arising in the knee with extra-articular invasion and six with TSGCT with intra-articular localization. The mean SUVmax of TSGCT with extra-articular invasion and those with intra-articular localization were 14.3 ± 6.00 and 5.94 ± 3.89, respectively. TSGCT with extra-articular invasion had significantly higher SUVmax than TSGCT with intra-articular localization (p < 0.05). Conclusions TSGCT revealed high FDG uptake. Furthermore, SUVmax was higher in diffused TSGCT with extra-articular invasion than in intra-articular localized TSGCT; this may reflect its local aggressiveness.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Imaging characteristics of tenosynovial giant cell tumors on 18F-fluorodeoxyglucose positron emission tomography/computed tomography: a retrospective observational study

Mizuta

Oshiro

Tsuha

et al. 2023

BMC Musculoskelet Disord

View full text Add to dashboard Cite

show abstract

“…The most characteristic feature of TGCT/PVNS is its intra-articular location, where it is exceedingly rare for a primary sarcoma or metastasis to originate. If focal intra-articular FDG uptake is associated with an isolated soft tissue mass on FDG PET/CT, MRI should be obtained for further evaluation, as TGCT/PVNS has a distinct heterogeneously low signal intensity on T1 and T2 weighted imaging due to hemosiderin deposits [ 57 ] and may occur more commonly than is generally appreciated [ 58 ] ( Figure 12 ).…”

Section: Jointmentioning

confidence: 99%

Musculoskeletal Pitfalls on Molecular Imaging Studies of Oncologic Patients: How to Stay Out of Trouble

Sarna,

Subhawong,

Sfakianaki

et al. 2024

Tomography

Self Cite

View full text Add to dashboard Cite

An increasing amount of molecular imaging studies are ordered each year for an oncologic population that continues to expand and increase in age. The importance of these studies in dictating further care for oncologic patients underscores the necessity of differentiating benign from malignant findings, particularly for a population in whom incidental findings are common. The aim of this review is to provide pictorial examples of benign musculoskeletal pathologies which may be found on molecular imaging and which may be mistaken for malignant processes. Imaging examples are provided in the form of radiographs, bone scintigraphy, computed tomography, and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) scans. Special attention is paid to specific features that help narrow the differential diagnosis and distinguish benign from malignant processes, with the goal of avoiding unnecessary invasive procedures.

show abstract

PET/CT in soft tissue sarcomas

Etchebehere

Munhoz

Casali

et al. 2022

Nuclear Medicine and Molecular Imaging

View full text Add to dashboard Cite

Significance of incidental intra-articular and peri-articular FDG avid foci on PET/CT

Cited by 5 publications

References 13 publications

Imaging characteristics of tenosynovial giant cell tumors on 18F-fluorodeoxyglucose positron emission tomography/computed tomography: a retrospective observational study

Imaging characteristics of tenosynovial giant cell tumors on 18F-fluorodeoxyglucose positron emission tomography/computed tomography: a retrospective observational study

Musculoskeletal Pitfalls on Molecular Imaging Studies of Oncologic Patients: How to Stay Out of Trouble

PET/CT in soft tissue sarcomas

Contact Info

Product

Resources

About